Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Real World Evidence Solutions Market, by Component
1.4.2 Europe Real World Evidence Solutions Market, by Therapeutic Area
1.4.3 Europe Real World Evidence Solutions Market, by End-user
1.4.4 Europe Real World Evidence Solutions Market, by Application
1.4.5 Europe Real World Evidence Solutions Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Scenario and Composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Real World Evidence Solutions Market
Chapter 4. Europe Real World Evidence Solutions Market by Component
4.1 Europe Services Market by Country
4.2 Europe Data Set Market by Country
Chapter 5. Europe Real World Evidence Solutions Market by Therapeutic Area
5.1 Europe Oncology Market by Country
5.2 Europe Cardiology Market by Country
5.3 Europe Neurology Market by Country
5.4 Europe Diabetes Market by Country
5.5 Europe Respiratory Market by Country
5.6 Europe Others Market by Country
Chapter 6. Europe Real World Evidence Solutions Market by End-user
6.1 Europe Healthcare Companies Market by Country
6.2 Europe Healthcare Payers Market by Country
6.3 Europe Healthcare Providers Market by Country
6.4 Europe Others Market by Country
Chapter 7. Europe Real World Evidence Solutions Market by Application
7.1 Europe Drug Development & Approvals Market by Country
7.2 Europe Medical Device Development & Approvals Market by Country
7.3 Europe Reimbursement/Coverage & Regulatory Decision Making Market by Country
7.4 Europe Post Market Safety & Adverse Events Monitoring Market by Country
Chapter 8. Europe Real World Evidence Solutions Market by Country
8.1 Germany Real World Evidence Solutions Market
8.1.1 Germany Real World Evidence Solutions Market by Component
8.1.2 Germany Real World Evidence Solutions Market by Therapeutic Area
8.1.3 Germany Real World Evidence Solutions Market by End-user
8.1.4 Germany Real World Evidence Solutions Market by Application
8.2 UK Real World Evidence Solutions Market
8.2.1 UK Real World Evidence Solutions Market by Component
8.2.2 UK Real World Evidence Solutions Market by Therapeutic Area
8.2.3 UK Real World Evidence Solutions Market by End-user
8.2.4 UK Real World Evidence Solutions Market by Application
8.3 France Real World Evidence Solutions Market
8.3.1 France Real World Evidence Solutions Market by Component
8.3.2 France Real World Evidence Solutions Market by Therapeutic Area
8.3.3 France Real World Evidence Solutions Market by End-user
8.3.4 France Real World Evidence Solutions Market by Application
8.4 Russia Real World Evidence Solutions Market
8.4.1 Russia Real World Evidence Solutions Market by Component
8.4.2 Russia Real World Evidence Solutions Market by Therapeutic Area
8.4.3 Russia Real World Evidence Solutions Market by End-user
8.4.4 Russia Real World Evidence Solutions Market by Application
8.5 Spain Real World Evidence Solutions Market
8.5.1 Spain Real World Evidence Solutions Market by Component
8.5.2 Spain Real World Evidence Solutions Market by Therapeutic Area
8.5.3 Spain Real World Evidence Solutions Market by End-user
8.5.4 Spain Real World Evidence Solutions Market by Application
8.6 Italy Real World Evidence Solutions Market
8.6.1 Italy Real World Evidence Solutions Market by Component
8.6.2 Italy Real World Evidence Solutions Market by Therapeutic Area
8.6.3 Italy Real World Evidence Solutions Market by End-user
8.6.4 Italy Real World Evidence Solutions Market by Application
8.7 Rest of Europe Real World Evidence Solutions Market
8.7.1 Rest of Europe Real World Evidence Solutions Market by Component
8.7.2 Rest of Europe Real World Evidence Solutions Market by Therapeutic Area
8.7.3 Rest of Europe Real World Evidence Solutions Market by End-user
8.7.4 Rest of Europe Real World Evidence Solutions Market by Application
Chapter 9. Company Profiles
9.1 IBM Corporation
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional & Segmental Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Acquisition and Mergers:
9.1.6 SWOT Analysis
9.2 Oracle Corporation
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 SWOT Analysis
9.3 PPD, Inc. (Thermo Fisher Scientific, Inc.)
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 SWOT Analysis
9.4 UnitedHealth Group, Inc. (Optum, Inc.)
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental Analysis
9.5 Syneos Health, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Recent strategies and developments:
9.5.4.1 Acquisition and Mergers:
9.6 IQVIA Holdings, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Recent strategies and developments:
9.6.4.1 Partnerships, Collaborations, and Agreements:
9.6.4.2 Acquisition and Mergers:
9.7 Medpace Holdings, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.8 ICON plc
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Recent strategies and developments:
9.8.4.1 Acquisition and Mergers:
9.9 PerkinElmer, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Product Launches and Product Expansions:
9.10. Parexel International Corporation (Phoenix Parentco, Inc.)
9.10.1 Company Overview
9.10.2 Recent strategies and developments:
9.10.2.1 Partnerships, Collaborations, and Agreements:
Unique Offerings 